# Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy

> **NCT07720258** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Center, Japan** · enrollment: 27 (estimated)

## Conditions studied

- Advanced Small Bowel Adenocarcinoma

## Interventions

- **DRUG:** Sacituzumab tirumotecan

## Key facts

- **NCT ID:** NCT07720258
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720258, "Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*